Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
35.94
+1.19 (3.42%)
Oct 9, 2025, 11:19 AM EDT - Market open
Dianthus Therapeutics Employees
Dianthus Therapeutics had 78 employees as of December 31, 2024. The number of employees increased by 25 or 47.17% compared to the previous year.
Employees
78
Change (1Y)
25
Growth (1Y)
47.17%
Revenue / Employee
$62,231
Profits / Employee
-$1,471,205
Market Cap
1.39B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 78 | 25 | 47.17% |
| Dec 31, 2023 | 53 | 21 | 65.63% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DNTH News
- 7 days ago - Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting - GlobeNewsWire
- 27 days ago - Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 4 weeks ago - Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering - GlobeNewsWire
- 4 weeks ago - Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference Call - Seeking Alpha
- 4 weeks ago - Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering - GlobeNewsWire
- 4 weeks ago - Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile - GlobeNewsWire
- 4 weeks ago - Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis - GlobeNewsWire
- 2 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire